Skip to main content
 

Investors & Media

Corporate Profile
At WAVE Life Sciences, we are driven by an unwavering passion and commitment to deliver on our mission of confronting challenging diseases by developing transformational therapies and empowering patients. We are utilizing our innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare and other serious genetically defined diseases. Given the versatility of our chemistry platform, WAVE’s deep, diverse pipeline spans multiple modalities including antisense, exon-skipping, and single-stranded RNAi.
Recent News
March 16, 2017
WAVE Life Sciences Reports Fourth Quarter and Full-Year 2016 Financial Results and Provides Business Update
On track to take first three lead programs into the clinic in 2017 Clinical trials expected to commence in Huntington’s disease mid-2017, Duchenne Muscular Dystrophy second half of 2017 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 16, 2017-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today reported financial results for the fourth quarter and ... 
February 6, 2017
WAVE Life Sciences to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 6, 2017-- WAVE Life Sciences Ltd. (NASDAQ:WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will be presenting at the following upcoming investor conferences: Leerink Partners Global Healthcare Conference 2017 Wednesday, February 15th at 1:30... 
January 6, 2017
WAVE Life Sciences 2017 Pipeline Update
Three Lead Neurology Programs to Enter Clinic in 2017 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 6, 2017-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced updates to its clinical pipeline for 2017. “2017 will be an important year for WAVE as we transition our two lead candidates in Huntington’s disease and our exon-skipping candida... 

view all

Upcoming Events
There are currently no events scheduled.

view all